13F filer · CIK 1697748 ↗
ARK Invest
You are looking at Q2 2017. See the latest, Q2 2026 →
Reported value
$513.6M
+48% on the quarter before
Positions
109
6 new · 1 sold out
Top 10
38.9%
of the value
Est. gain
+$41.7M
on stocks held all quarter
Est. return
+12.6%
on those stocks since Q1 2017
Positions as of Jun 30, 2017, from ARK Invest's 13F filing with the SEC. A 13F lists a manager's US-listed stocks and options at a quarter end and is filed up to 45 days later, so the fund may hold something else today. It leaves out short positions, cash and holdings outside the US.
Portfolio at a glance
- New
- Added
- Cut
- Same
- Options
Each tile is a position, sized by its share, colored by what the fund did with it since Q1 2017. Striped tiles are options.
Largest buys
Since Q1 2017, by estimated size: the change in shares at the quarter-end price, since a 13F gives no trade prices. Percentages are the position's share of the portfolio, before and after.
- Nvidia~$8.1MAdded · 2.2% → 3.6%+56,138 shares
- Amazon~$8.1MAdded · 5.5% → 5.6%+8,322 shares
- Juno Therapeutics Inc~$7.5MAdded · 1.6% → 2.9%+252,029 shares
- Alphabet~$6.1MAdded · 2.2% → 2.8%+6,742 shares
- Xilinx Inc~$5.9MAdded · 1.4% → 2.2%+91,460 shares
- Twilio~$5.6MAdded · 0.2% → 1.2%+191,201 shares
- Tesla~$5.5MAdded · 1.8% → 2.7%+15,186 shares
- Medidata Solutions Inc~$5.1MAdded · 0.2% → 1.1%+65,378 shares
- Akamai~$4.7MAdded · 0.1% → 1.0%+95,334 shares
- Editas Medicine Inc~$4.7MAdded · 1.5% → 1.7%+280,265 shares
Largest sells
Since Q1 2017, by estimated size: the change in shares at the quarter-end price, since a 13F gives no trade prices. Percentages are the position's share of the portfolio, before and after.
- Athenahealth Inc~$4.6MCut · 7.4% → 5.3%−32,738 shares
- Stratasys Ltd~$3.0MCut · 8.1% → 5.6%−129,347 shares
- Illumina Inc~$2.8MCut · 5.9% → 3.5%−16,076 shares
- IBM~$2.8MCut · 1.1% → 0.1%−17,987 shares
- Schwab Charles Corp New~$2.6MSold out · 0.7% → 0.0%−62,530 shares
- PayPal~$1.2MCut · 1.8% → 1.2%−22,262 shares
- General Mtrs Co~$301,810Cut · 0.3% → 0.1%−8,637 shares
- Qualcomm~$115,917Cut · 1.5% → 0.9%−2,099 shares
- Biogen Inc~$99,886Cut · 0.3% → 0.2%−368 shares
- Alnylam Pharmaceuticals Inc~$75,646Cut · 0.1% → 0.1%−948 shares
Holdings
As of Jun 30, 2017. Changes are in shares against Mar 31, 2017, so a price move alone never reads as a buy or a sale.
| Holding | Value | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| AmazonCOM · shares +39% · price +9.2% | 5.6% | $28.9M | +$1.8M | ||||||||
| Stratasys LtdSHS · shares −9.5% · price +13.8% | 5.6% | $28.8M | +$3.5M | ||||||||
| Athenahealth IncCOM · shares −14% · price +24.7% | 5.3% | $27.3M | +$5.4M | ||||||||
| BaiduSPON ADR REP A · shares +31% · price +3.7% | 3.6% | $18.4M | +$498,314 | ||||||||
| NvidiaCOM · shares +79% · price +32.7% | 3.6% | $18.3M | +$2.5M | ||||||||
| Illumina IncCOM · shares −13% · price +1.7% | 3.5% | $18.0M | +$299,185 | ||||||||
| Twitter IncCOM · shares +28% · price +19.5% | 3.2% | $16.5M | +$2.1M | ||||||||
| Juno Therapeutics IncCOM · shares +102% · price +34.7% | 2.9% | $15.0M | +$1.9M | ||||||||
| AlphabetCAP STK CL C · shares +74% · price +9.5% | 2.8% | $14.4M | +$720,424 | ||||||||
| Proto Labs IncCOM · shares +15% · price +31.6% | 2.7% | $14.0M | +$2.9M | ||||||||
| TeslaCOM · shares +67% · price +29.9% | 2.7% | $13.7M | +$1.9M | ||||||||
| Bluebird Bio IncCOM · shares +45% · price +15.6% | 2.4% | $12.6M | +$1.2M | ||||||||
| Kite Pharma IncCOM · shares +29% · price +32.1% | 2.3% | $11.7M | +$2.2M | ||||||||
| Splunk IncCOM · shares +69% · price −8.7% | 2.2% | $11.5M | −$645,408 | ||||||||
| Xilinx IncCOM · shares +112% · price +11.1% | 2.2% | $11.1M | +$524,291 | ||||||||
| 2u IncCOM · shares +28% · price +18.3% | 2.1% | $11.0M | +$1.3M | ||||||||
| Foundation Medicine IncCOM · shares +6.3% · price +23.3% | 2.1% | $10.9M | +$1.9M | ||||||||
| MetaCL A · shares +25% · price +6.3% | 2.1% | $10.9M | +$517,936 | ||||||||
| Hortonworks IncCOM · shares +5.9% · price +31.3% | 2.1% | $10.8M | +$2.4M | ||||||||
| SalesforceCOM · shares +38% · price +5.0% | 1.9% | $9.6M | +$331,347 | ||||||||
| Invitae CorpCOM · shares +30% · price −13.6% | 1.8% | $9.4M | −$1.1M | ||||||||
| NetflixCOM · shares +37% · price +1.1% | 1.8% | $9.4M | +$72,535 | ||||||||
| Ionis Pharmaceuticals IncCOM · shares +39% · price +26.5% | 1.8% | $9.0M | +$1.4M | ||||||||
| Seres Therapeutics IncCOM · shares +21% · price +0.3% | 1.7% | $8.6M | +$19,321 | ||||||||
| Editas Medicine IncCOM · shares +122% · price −24.8% | 1.7% | $8.6M | −$1.3M | ||||||||
| Total · 109 positions | 100% | $513.6M | +$41.7M |
Price is a stock's reported value over its shares at the quarter end. The estimated gain is the shares held at both quarter ends times the change in that price: shares bought or sold during the quarter add nothing, options are left out, and a stock split is read into the earlier share count and price.
What made money
From Q1 2017 to Q2 2017: 103 stocks held throughout, up $41.7M (+12.6%).
- Athenahealth Inc+$5.4M+25%
- Stratasys Ltd+$3.5M+14%
- Proto Labs Inc+$2.9M+32%
- Nvidia+$2.5M+33%
- Hortonworks Inc+$2.4M+31%
- Organovo Hldgs Inc−$339,450−17%
- Splunk Inc−$645,408−9%
- Invitae Corp−$1.1M−14%
- Editas Medicine Inc−$1.3M−25%
- Cerus Corp−$1.4M−44%
Estimated as in the holdings table: shares held at both quarter ends times the change in price; options left out.
Reported value by quarter
The total value of each quarter's 13F at that quarter end. It moves with prices as well as with buying and selling. Pick a quarter to see what the fund held then.
Every quarter's filing
| Quarter | Reported value | Filing | |
|---|---|---|---|
| Q2 2026 | Aug 14, 2026 | $15.40B+20% | SEC ↗ |
| Q1 2026 | May 12, 2026 | $12.86B−15% | SEC ↗ |
| Q4 2025 | Feb 11, 2026 | $15.07B−10% | SEC ↗ |
| Q3 2025 | Nov 12, 2025 | $16.80B+23% | SEC ↗ |
| Q2 2025 | Jul 30, 2025 | $13.64B+37% | SEC ↗ |
| Q1 2025 | May 7, 2025 | $9.99B−17% | SEC ↗ |
| Q4 2024 | Feb 4, 2025 | $12.01B+10% | SEC ↗ |
| Q3 2024 | Oct 31, 2024 | $10.93B−3% | SEC ↗ |
| Q2 2024 | Jul 26, 2024 | $11.27B−22% | SEC ↗ |
| Q1 2024 | Apr 18, 2024 | $14.44B−14% | SEC ↗ |
| Q4 2023 | Jan 17, 2024 | $16.89B+29% | SEC ↗ |
| Q3 2023 | Oct 18, 2023 | $13.07B−13% | SEC ↗ |
| Q2 2023 | Jul 10, 2023 | $15.10B+4% | SEC ↗ |
| Q1 2023 | Apr 17, 2023 | $14.55B+26% | SEC ↗ |
| Q4 2022 | Jan 24, 2023 | $11.54B−20% | SEC ↗ |
| Q3 2022 | Oct 17, 2022 | $14.35B−15% | SEC ↗ |
| Q2 2022 | Jul 11, 2022 | $16.91B−29% | SEC ↗ |
| Q1 2022 | Apr 18, 2022 | $23.96B−28% | SEC ↗ |
| Q4 2021 | Jan 28, 2022 | $33.08B−21% | SEC ↗ |
| Q3 2021 | Nov 12, 2021 | $41.64B−23% | SEC ↗ |
| Q2 2021 | Aug 5, 2021 | $53.74B+7% | SEC ↗ |
| Q1 2021 | May 13, 2021 | $50.34B+34% | SEC ↗ |
| Q4 2020 | Feb 12, 2021 | $37.59B+123% | SEC ↗ |
| Q3 2020 | Oct 30, 2020 | $16.86B+81% | SEC ↗ |
| Q2 2020 | Aug 11, 2020 | $9.30B+132% | SEC ↗ |
| Q1 2020 | May 14, 2020 | $4.01B+1% | SEC ↗ |
| Q4 2019 | Jan 31, 2020 | $3.96B−13% | SEC ↗ |
| Q3 2019 | Nov 12, 2019 | $4.58B+15% | SEC ↗ |
| Q2 2019 | Jul 30, 2019 | $3.97B+13% | SEC ↗ |
| Q1 2019 | May 13, 2019 | $3.50B+42% | SEC ↗ |
| Q4 2018 | Feb 11, 2019 (amended) | $2.46B−26% | SEC ↗ |
| Q3 2018 | Nov 7, 2018 | $3.31B+21% | SEC ↗ |
| Q2 2018 | Aug 7, 2018 | $2.73B+36% | SEC ↗ |
| Q1 2018 | May 14, 2018 | $2.01B+60% | SEC ↗ |
| Q4 2017 | Feb 12, 2018 | $1.26B+53% | SEC ↗ |
| Q3 2017 | Nov 9, 2017 | $819.3M+60% | SEC ↗ |
| Q2 2017 | Aug 11, 2017 | $513.6M+48% | SEC ↗ |
| Q1 2017 | May 15, 2017 | $346.9M+26% | SEC ↗ |
| Q4 2016 | Feb 13, 2017 | $274.9M | SEC ↗ |